Boston, MA. June 19, 2019. The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients […] READ MORE
MADRID, Spain. June 13, 2019 – Results of the first clinical trial conducted through the Lupus Research Alliance Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019. The study, called VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), showed that a custom smartphone app allowed people with lupus […] READ MORE
NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their […] READ MORE
NEW YORK, NY – May 29. Researchers partly funded by the Lupus Research Alliance (LRA) have found possible new targets for drugs to treat lupus after snapping the first close-up of a molecule that promotes inflammation. The molecule that Target Identification in Lupus (TIL) grant recipient Dr. Roger Greenberg at University of Pennsylvania and Dr. […] READ MORE
NEW YORK, NY – May 7, 2019. The 10th annual Lupus Luminary Luncheon for Science honored the accomplishments of luminaries transforming lupus and other arenas. Campbell Brown, VP of Global News Partnerships at Facebook was recognized as a Woman of Achievement and lupus research supporter. This year’s Woman of Achievement in Clinical Research Award went […] READ MORE
NEW YORK, NY. May 1 — The Lupus Research Alliance (LRA) launches its Breaking through for Lupus Research: 20 Years of Progress campaign today in observance of Lupus Awareness Month. The organization will be celebrating the scientific discoveries that have brought the greatest hope to the lupus community. The LRA has invested over $200 million […] READ MORE
NEW YORK, NY. April 29. Lupus can harm many organs in the body, including the kidneys. A new study led by Dr. Hans Haecker of St. Jude Children’s Research Hospital in Memphis found that the cells that provoke kidney damage are different than those that injure other organs. In part funded by a grant from […] READ MORE
NEW YORK, NY. March 28 – Lupus Research Alliance earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. Awarded for its strong financial health and commitment to accountability and transparency, the Lupus Research Alliance has earned this distinction every year since its founding in 2016. Using objective analysis, Charity Navigator has […] READ MORE
WASHINGTON, DC – March 19. Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, celebrates its 15th Annual Advocate for Lupus Research Day on Capitol Hill today, sounding the need for increased federal funding to further advance new lupus treatments and a cure. Advocates representing the Lupus Research Alliance are on the […] READ MORE
NEW YORK, NY. March 6, 2019. Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide […] READ MORE
New York, NY– March 1. The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916). TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human […] READ MORE
February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery. In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […] READ MORE
